APA (7th ed.) Citation

Petrylak, D. P., Vogelzang, N. J., Chatta, K., Fleming, M. T., Smith, D. C., Appleman, L. J., . . . Israel, R. J. (2020). PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study. The Prostate, 80(1), 99-108. https://doi.org/10.1002/pros.23922

Chicago Style (17th ed.) Citation

Petrylak, Daniel P., et al. "PSMA ADC Monotherapy in Patients with Progressive Metastatic Castration‐resistant Prostate Cancer Following Abiraterone And/or Enzalutamide: Efficacy and Safety in Open‐label Single‐arm Phase 2 Study." The Prostate 80, no. 1 (2020): 99-108. https://doi.org/10.1002/pros.23922.

MLA (9th ed.) Citation

Petrylak, Daniel P., et al. "PSMA ADC Monotherapy in Patients with Progressive Metastatic Castration‐resistant Prostate Cancer Following Abiraterone And/or Enzalutamide: Efficacy and Safety in Open‐label Single‐arm Phase 2 Study." The Prostate, vol. 80, no. 1, 2020, pp. 99-108, https://doi.org/10.1002/pros.23922.